JP2020528447A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020528447A5 JP2020528447A5 JP2020504405A JP2020504405A JP2020528447A5 JP 2020528447 A5 JP2020528447 A5 JP 2020528447A5 JP 2020504405 A JP2020504405 A JP 2020504405A JP 2020504405 A JP2020504405 A JP 2020504405A JP 2020528447 A5 JP2020528447 A5 JP 2020528447A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutical composition
- compound
- composition according
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023114928A JP2023134636A (ja) | 2017-07-24 | 2023-07-13 | 神経変性および炎症性疾患の治療に使用するためのｃｄ３８と特異的に結合する化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17315006.1 | 2017-07-24 | ||
| EP17315006.1A EP3434692A1 (en) | 2017-07-24 | 2017-07-24 | Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases |
| PCT/EP2018/070064 WO2019020643A1 (en) | 2017-07-24 | 2018-07-24 | COMPOUND BINDING SPECIFICALLY TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023114928A Division JP2023134636A (ja) | 2017-07-24 | 2023-07-13 | 神経変性および炎症性疾患の治療に使用するためのｃｄ３８と特異的に結合する化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020528447A JP2020528447A (ja) | 2020-09-24 |
| JP2020528447A5 true JP2020528447A5 (https=) | 2021-09-02 |
Family
ID=59626538
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020504405A Pending JP2020528447A (ja) | 2017-07-24 | 2018-07-24 | 神経変性および炎症性疾患の治療に使用するためのｃｄ３８と特異的に結合する化合物 |
| JP2023114928A Pending JP2023134636A (ja) | 2017-07-24 | 2023-07-13 | 神経変性および炎症性疾患の治療に使用するためのｃｄ３８と特異的に結合する化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023114928A Pending JP2023134636A (ja) | 2017-07-24 | 2023-07-13 | 神経変性および炎症性疾患の治療に使用するためのｃｄ３８と特異的に結合する化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210087290A1 (https=) |
| EP (2) | EP3434692A1 (https=) |
| JP (2) | JP2020528447A (https=) |
| CN (1) | CN111108127A (https=) |
| AU (1) | AU2018308649A1 (https=) |
| CA (1) | CA3070756A1 (https=) |
| WO (1) | WO2019020643A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200345725A1 (en) | 2019-01-11 | 2020-11-05 | Omeros Corporation | Methods and Compositions for Treating Cancer |
| WO2021021986A1 (en) | 2019-07-31 | 2021-02-04 | Ribon Therapeutics, Inc. | Heterobicyclic amides as inhibitors of cd38 |
| EP4054714A4 (en) * | 2019-11-07 | 2023-12-06 | Ohio State Innovation Foundation | METHODS AND COMPOSITIONS FOR SELECTIVE INTRACELLULAR DELIVERY OF CD38 INHIBITORS |
| EP3943505A1 (en) * | 2020-07-22 | 2022-01-26 | Encefa | Cd38-binding cd31 peptides and uses thereof |
| WO2022152823A1 (en) | 2021-01-14 | 2022-07-21 | Morphosys Ag | Anti-cd38 antibodies and their uses |
| HRP20251111T1 (hr) | 2021-01-29 | 2025-11-21 | Boehringer Ingelheim International Gmbh | Azakinolini kao inhibitori cd38 |
| TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體 |
| WO2024090500A1 (ja) | 2022-10-28 | 2024-05-02 | 日本精工株式会社 | 回転支持装置、及び軸支持装置の支持機構位置調整機構 |
| WO2026075985A1 (en) * | 2024-10-01 | 2026-04-09 | Neolaia Inc. | Quinoline- and quinazoline-carboxamide derivatives as cd38 inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| ATE542830T1 (de) | 2006-12-04 | 2012-02-15 | Pasteur Institut | Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel |
| DK2580243T3 (da) * | 2010-06-09 | 2020-01-13 | Genmab As | Antibodies against human cd38 |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| US20120328526A1 (en) | 2011-06-27 | 2012-12-27 | University Of Maryland, Baltimore | Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof |
| US20150093399A1 (en) | 2013-08-28 | 2015-04-02 | Bioasis Technologies, Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
| WO2016024246A1 (en) | 2014-08-14 | 2016-02-18 | Universita' Degli Studi Di Roma 'la Sapienza' | A therapeutic use of naadp and/or tcp2 antagonists |
| MX386886B (es) * | 2014-09-09 | 2025-03-12 | Janssen Biotech Inc | Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias. |
| TWI769982B (zh) | 2015-06-24 | 2022-07-11 | 日商Ｊｃｒ製藥股份有限公司 | 通過血腦障壁之抗人類運鐵蛋白受體抗體 |
| HRP20240338T1 (hr) * | 2015-06-24 | 2024-05-24 | Janssen Biotech, Inc. | Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38 |
| WO2017096246A1 (en) * | 2015-12-03 | 2017-06-08 | Temple University-Of The Commonwealth System Of Higher Education | Modulation of nad+ and nad+ metabolic pathways for treatment of disease |
-
2017
- 2017-07-24 EP EP17315006.1A patent/EP3434692A1/en not_active Withdrawn
-
2018
- 2018-07-24 US US16/633,749 patent/US20210087290A1/en active Pending
- 2018-07-24 AU AU2018308649A patent/AU2018308649A1/en not_active Abandoned
- 2018-07-24 JP JP2020504405A patent/JP2020528447A/ja active Pending
- 2018-07-24 CA CA3070756A patent/CA3070756A1/en active Pending
- 2018-07-24 WO PCT/EP2018/070064 patent/WO2019020643A1/en not_active Ceased
- 2018-07-24 EP EP18753069.6A patent/EP3658586A1/en not_active Withdrawn
- 2018-07-24 CN CN201880061584.XA patent/CN111108127A/zh active Pending
-
2023
- 2023-07-13 JP JP2023114928A patent/JP2023134636A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020528447A5 (https=) | ||
| AU2022283769B2 (en) | Neuroactive steroids, compositions, and uses thereof | |
| Pradhan et al. | Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis | |
| US20010018053A1 (en) | Methods for treating disease states comprising administration of low levels of antibodies | |
| WO2007002516A3 (en) | Improved dosage forms for movement disorder treatment | |
| BR0315283A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de doenças neurológicas ou de doenças inflamatórias do trato respiratório superior | |
| JP5916746B2 (ja) | 認知障害を処置するためのピリダジン誘導体、組成物、および方法 | |
| RU2017103446A (ru) | УЛУЧШЕННЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Аβ-ПРОТОФИБРИЛЛЫ | |
| BRPI0417959A (pt) | anticorpo ou fragmento funcional deste, composição farmcêutica, método para tratamento ou profilaxia de acidente vascular cerebral e outras doenças/distúrbios neurológicos em um ser humano, uso de um anticorpo anti-nogo, e, métodos para inibir a neurodegeneração e/ou promover a recuperação funcional em um paciente humano, para promover o crescimento axonal, para produzir um anticorpo anti-nogo e para produzir uma composição farmacêutica intravenosamente administrável | |
| CN113490505A (zh) | 用于治疗tau蛋白病的tau肽抗原及与其结合的抗体 | |
| US20200262864A1 (en) | Deuterated forms of aminosterols and methods of using the same | |
| TWI717848B (zh) | 抗體於治療神經退化性疾病的用途 | |
| JP2019534327A5 (https=) | ||
| Osinalde et al. | Impaired proteostasis in rare neurological diseases | |
| JP2023507569A (ja) | 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法 | |
| JP6347807B2 (ja) | 疼痛制御及び脱髄損傷の回復におけるｎ−２−ヒドロキシ−エチル−ピペラジン−ｎ’−２−エタンスルホン酸（ｈｅｐｅｓ）の役割 | |
| Pérez de Llano et al. | Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab. | |
| Black et al. | Severe imipramine-induced myoclonus in a patient with psychotic bipolar depression, catatonia, and schizencephaly | |
| Panzer et al. | Anti-NMDA Receptor Encephalitis and Other Autoimmune and Paraneoplastic Movement Disorders | |
| Hardjo Lugito et al. | Worsening muscle weakness in myasthenia gravis patient suffering dengue infection | |
| Panzer et al. | Anti-NMDA Receptor Encephalitis | |
| Shinno et al. | Atypical gradual progression in rapid-onset dystonia-parkinsonism with a rare ATP1A3 variant and the long-term effectiveness of botulinum toxin therapy | |
| Khadilkar et al. | Chronic inflammatory demyelinating polyradiculoneuropathy | |
| Khadilkar et al. | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | |
| Omar | USMLE Step 2 CK Plus EBOOK: USMLE Step 2 CK Plus EBOOK |